iShares Genomics Immunology and Healthcare ETF (IDNA)

iShares Genomics Immunology and Healthcare ETF (IDNA $21.42)
- $21.42 P/E (TTM): 19.53X Cap: $109M
- View IDNA Profile
- View Questions on IDNA

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

BMO Equal Weight US Health Care Hedged to CAD Index ETF (ZUH $61.01)
- $61.01 P/E (TTM): 21.92X Cap: $270M
- View ZUH Profile
- View Questions on ZUH
iShares Biotechnology ETF (IBB $129.12)
- $129.12 P/E (TTM): 41.5X Cap: $5.42B
- View IBB Profile
- View Questions on IBB
iShares U.S. Medical Devices ETF (IHI $59.96)
- $59.96 P/E (TTM): 105.73X Cap: $4.32B
- View IHI Profile
- View Questions on IHI
iShares U.S. Pharmaceuticals ETF (IHE $66.95)
- $66.95 P/E (TTM): 57.72X Cap: $557M
- View IHE Profile
- View Questions on IHE
iShares Genomics Immunology and Healthcare ETF (IDNA $21.42)
- $21.42 P/E (TTM): 19.53X Cap: $109M
- View IDNA Profile
- View Questions on IDNA

Q: Can you recommend one or more etf's that would provide exposure to the health industry including medical devices, genomics, biotech, big pharma etc. Covered call etf's in these sectors would also be of interest. Thanks

Read Answer Asked by Ian on July 12, 2022

iShares Biotechnology ETF (IBB $129.12)
- $129.12 P/E (TTM): 41.5X Cap: $5.42B
- View IBB Profile
- View Questions on IBB
iShares Genomics Immunology and Healthcare ETF (IDNA $21.42)
- $21.42 P/E (TTM): 19.53X Cap: $109M
- View IDNA Profile
- View Questions on IDNA

Q: Hello 5I
Which path will be the best to follow from a growth prospective with the recent success of the mRNA COVID vaccines, the research that is going into cellular and genetic treatments of diseases and chronic conditions and cancers, the baby boomer population that probably hold a fair portion of the wealth and are hoping to stay healthier longer? Any companies and or ETFS that stand out? Or is this the wrong line of thinking?
Thank you for all you do and have done for me.

Read Answer Asked by Jeremy on March 04, 2021